Drugs / Norcantharidin
Norcantharidin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04673396 | Sep 2020 → Dec 2021 | cancer | Beijing Nuokangda Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norcantharidin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04673396 ↗ |
| Known as | Demethylcantharidin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237212 ↗ |
| Known as | Isocantharidin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237212 ↗ |
| Known as | NSC-14003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237212 ↗ |
| Known as | NSC-59023 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237212 ↗ |
| Modality | Small molecule | — CHEMBL1237212 ↗ |
| Route | Other | “administered by instillation at a rate of 200 mL/h” NCT04673396 ↗ |